SLC5A2 and sarcopenia: The hypothesis that SGLT2 inhibitors may induce sarcopenia stems from the idea that the glucosuria-induced gluconeogenesis not only triggers lipolysis but may also initiate proteolysis in skeletal muscle by utilizing amino acids as substrates [17].